InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar pmtrain (90.73) Submitted: 2/10/2009 5:26:34 AM : Outperform Start Price: $18.62 ITMN Score: -98.18

hpc trials are taking this company higher almost daily feb 2009 (best owned performer)

Featured Broker Partners


Advertisement